A survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
Jens Grueger
Advertisement
Director for Market Access and Pricing in Healthcare, Boston Consulting Group
Articles by Jens Grueger
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
Direct-to-patient: pharma’s next power move
3
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
